Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “rifaximin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 11
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 11 pipeline programs matching "rifaximin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

11 results for “rifaximin” Back to intelligence hub

Search results

  1. Rifaximin

    The First People's Hospital of Lianyungang

    Crohn Disease

    phase 3 small molecule active

    1 trial
  2. Rifaximin

    Hospital Authority, Hong Kong

    Decompensated Cirrhosis

    phase 3 small molecule terminated

    1 trial
  3. Rifaximin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial
  4. Rifaximin

    COLLEGIUM PHARMACEUTICAL, INC

    ACS - Acute Coronary Syndrome

    approved small molecule active

    1 trial
  5. Rifaximin

    United Therapeutics Europe Ltd

    Nonalcoholic Fatty Liver Disease

    approved small molecule terminated

    1 trial
  6. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial
  7. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial
  8. Rifaximin Oral Tablet

    Hospital Authority, Hong Kong

    Irritable Bowel Syndrome With Diarrhea

    approved small molecule completed

    1 trial
  9. Rifaximin

    United Therapeutics Europe Ltd

    Tropical Enteropathy

    small molecule completed

    1 trial
  10. Rifaximin

    United Therapeutics Europe Ltd

    Travelers' Diarrhea

    small molecule completed

    1 trial
  11. Rifaximin

    The First People's Hospital of Lianyungang

    Bacterial Overgrowth Syndrome Small Bowel

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.